Lampalizumab
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].
Product Specifications
CAS Number
1278466-20-8
Product Name Alternative
RG 7417; TNX 234; Anti-CFD Recombinant Antibody
UNSPSC
12352203
Target
Complement System
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lampalizumab.html
Purity
99.46
Solubility
H2O
Smiles
[Lampalizumab]
Molecular Weight
(143.8 kDa)
References & Citations
[1]Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102 (3) :466-475.|[2]Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100 (1) :122-7.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682922-500 1x 500 µL
Uroplakin 1A (Urothelial Differentiation Marker) (UPK1A/2922), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
